Moreover, the activation of ISR due to reduced OTUD3 expression confers resistance of liver cancer cells to sorafenib, and the combined use of the ISR inhibitor ISRIB significantly enhances the sensitivity of liver cancer cells to sorafenib172. This evidence concerns the gene OTUD3 and liver cancer.